Abstract

BackgroundTau is an axonal protein that binds to and regulates microtubule function. Hyper-phosphorylation of Tau reduces its binding to microtubules and it is associated with β-amyloid deposition in Alzheimer’s disease. Paradoxically, Tau reduction may prevent β-amyloid pathology, raising the possibility that Tau mediates intracellular Aβ clearance. The current studies investigated the role of Tau in autophagic and proteasomal intracellular Aβ1-42 clearance and the subsequent effect on plaque deposition.ResultsTau deletion impaired Aβ clearance via autophagy, but not the proteasome, while introduction of wild type human Tau into Tau−/− mice partially restored autophagic clearance of Aβ1-42, suggesting that exogenous Tau expression can support autophagic Aβ1-42 clearance. Tau deletion impaired autophagic flux and resulted in Aβ1-42 accumulation in pre-lysosomal autophagic vacuoles, affecting Aβ1-42 deposition into the lysosome. This autophagic defect was associated with decreased intracellular Aβ1-42 and increased plaque load in Tau−/− mice, which displayed less cell death. Nilotinib, an Abl tyrosine kinase inhibitor that promotes autophagic clearance mechanisms, reduced Aβ1-42 only when exogenous human Tau was expressed in Tau−/− mice.ConclusionsThese studies demonstrate that Tau deletion affects intracellular Aβ1-42 clearance, leading to extracellular plaque.Electronic supplementary materialThe online version of this article (doi:10.1186/1750-1326-9-46) contains supplementary material, which is available to authorized users.

Highlights

  • Tau is an axonal protein that binds to and regulates microtubule function

  • We previously demonstrated that lentiviral Aβ1-42 expression leads to phosphorylated Tau (p-Tau) accumulation and inhibition of both the proteasome and autophagy [13,14,16,17], while the Abl tyrosine kinase inhibitor Nilotinib increases autophagic Aβ and p-Tau clearance, leading to decreased plaque levels in Alzheimer’s disease (AD) models [14,16]

  • Autophagy and the proteasome contribute to p-Tau and Aβ1-42 clearance We previously demonstrated that impaired autophagic clearance of intracellular Aβ leads to more plaque deposition in parkin deficient mice [13,14,16,17]

Read more

Summary

Introduction

Tau is an axonal protein that binds to and regulates microtubule function. Hyper-phosphorylation of Tau reduces its binding to microtubules and it is associated with β-amyloid deposition in Alzheimer’s disease. Tau reduction may prevent β-amyloid pathology, raising the possibility that Tau mediates intracellular Aβ clearance. Two major pathologies that are linked to Alzheimer’s disease (AD), include extracellular β-amyloid (Aβ) plaques and intracellular neurofibrillary tangles (NFTs) comprised of hyper-phosphorylated Tau (p-Tau) [1]. We previously demonstrated that lentiviral Aβ1-42 expression leads to p-Tau accumulation and inhibition of both the proteasome and autophagy [13,14,16,17], while the Abl tyrosine kinase inhibitor Nilotinib increases autophagic Aβ and p-Tau clearance, leading to decreased plaque levels in AD models [14,16]. Our data suggest that Tau deletion inhibits autophagic flux, resulting in reduction of intracellular Aβ degradation and increased plaque deposition

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.